Selective IL-1 activity on CD8+ T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradication

• Bram Van Den Eeckhout,
• Leander Huyghe,
• Sandra Van Lint,
• Elianne Burg,
• Stéphane Plaisance,
• Frank Peelman,
• Anje Cauwels,
• Gilles Uzé,
• Niko Kley,
• Sarah Gerlo,
• Jan Tavernier

Affiliations

Bram Van Den Eeckhout

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Leander Huyghe

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Sandra Van Lint

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Elianne Burg

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Stéphane Plaisance

VIB Nucleomics Core, Leuven, Belgium

Frank Peelman

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Anje Cauwels

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Gilles Uzé

IRMB, University Montpellier, INSERM, CNRS, Montpellier, France

Niko Kley

Orionis Biosciences Inc, Waltham, Massachusetts, USA

Sarah Gerlo

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium

Jan Tavernier

VIB-UGent Center for Medical Biotechnology, Ghent, Belgium